



Appendix: Grace Macalino Grant Funding, Publications, and Presentations

GRANT FUNDING OBTAINED

| Grant Title | Funding Agency/Type | Role | Total Direct Costs | Period |
|---|--|------------------------|--------------------|-----------|
| <i>Current</i> | | | | |
| Assessment of Gonorrhea Resistance Among U.S. Military Personnel and Overseas At-Risk Civilian Populations | Global Emerging Infections Surveillance (GEIS) | Principal Investigator | \$680,000/year | 2011-2017 |
| Sexually Transmitted Infections among HIV seropositive active duty members and their beneficiaries in the HIV NHS | IDCRP, NIAID Intramural funding | Principal Investigator | \$175,000/year | 2011-2017 |
| Identifying social networks among DoD beneficiaries | IDCRP, NIAID Intramural funding | Principal Investigator | \$250,000/year | 2014-2017 |
| Three anatomic site GC/CT testing among HIV+ active duty members | Global Emerging Infections Surveillance (GEIS) | Co-Investigator | \$225,000/year | 2014-2017 |
| CT typing among at-risk HIV-DoD beneficiaries | Global Emerging Infections Surveillance (GEIS) | Co-Investigator | \$180,000/year | 2015-2017 |
| <i>Completed</i> | | | | |
| Access to Health Resources and HIV/AIDS for Previously Incarcerated Individual & Their Families. | Langeloth Foundation | Principal Investigator | \$300,000 | 2008-2011 |
| Health Science Academy Replication Planning | GlaxoSmithKline | Co-Investigator | \$100,000 | 2008-2009 |
| Reducing HIV Heterosexual Risk among African-American Men | CDC | Co-Investigator | \$270,000/year | 2007-2010 |
| Racial Disparities Among Methadone Recipients in Rhode Island | NIH/NIDA-R01 | Co-Investigator | \$1,250,000 | 2006-2010 |

| | | | | |
|---|---|--|---------------|-----------|
| Brooklyn Health Disparities Research Center | NIH/National Center for Minority Health and Health Disparities Project EXPORT | Co-Investigator | \$1.4 million | 2006-2008 |
| Prescription Opioids, Internet Pharmacies and Self Treatment of Chronic Pain | NIH/NIDA-R21 | Co-Investigator; PI of Sub with UMass Medical School | \$275,000 | 2006-2010 |
| Adulterants, Drugs, Co-Ingredients and Associated HIV Risks | NIH/NIDA-R01 | Co-Investigator; PI of Sub with UMass Medical School | \$1,657,563 | 2005-2009 |
| Health Science Academy | Out of School Time Program (OSTP) | | \$390,000 | 2005-2009 |
| Minority Supplement: Access to HIV/HCV Prevention after Syringe Law Change | NIH/NIDA | Principal Investigator | \$64,655 | 2003-2004 |
| Outreach and Methadone for Former Prisoners | DHHS/SAMHSA GFA# TI-02-009 | Co-Investigator; PI of Sub: Miriam Hospital | \$174,835 | 2002-2007 |
| Center for Metabolic Research on HIV and Drug Abuse | NIH/NIAID-P30 P30-DA-13868 | Co-Investigator; PI of Sub: Tufts Univ | \$291,163 | 2002-2006 |
| Access to HIV/HCV Prevention after Syringe Law Change | NIH/NIDA-R01 DA-01-008 | Principal Investigator | \$1,242,155 | 2001-2006 |
| Analyzing Multiple Process Data in Studies of HIV/AIDS, AI-50505-01 National Institute of Allergies and Infectious Diseases | NIH/NIAID | Co-Investigator | \$921,953 | 2001-2004 |
| Directly Observed HAART for Active Substance Abusers | NIH/NIDA-R01 DA13767-01 | Co-Investigator; PI of Sub: Miriam Hospital | \$386,486 | 2000-2006 |
| Physician Patient IDU Pilot Program | DHHS/SAMHSA | Co-Investigator; PI of Sub: Miriam Hospital | \$1,284,805 | 2000-2003 |
| Blood-borne Infections Among Imprisoned Drug Users, U64-CCU31492 | CDC | Principal Investigator | \$1,774,165 | 1997-2001 |

PUBLICATIONS IN PEER REVIEWED JOURNALS

1. Lawrence JM, Engh C, **Macalino GE**. Revision total hip arthroplasty: long term results without cement. *Orthop Clinics North Am* 1993 Oct; 24(4):635-644.
2. Engh CA, Hooten Jr. JP, Zettl-Schaffer KF, Ghaffarpour M, McGovern TF, **Macalino GE**, Zicat BA. Porous-coated total hip replacement. *Clin Orthop* 1994 Jan; 298:89-96.
3. Lawrence JM, Engh C, **Macalino GE**, Lauro GR. Outcome of revision hip arthroplasty done without cement. *J Bone Joint Surg Am* 1994 Jul;76(7):965-973.
4. Sotereanos NG, Engh CA, Glassman AH, **Macalino GE**, Engh Jr. CA. Cementless femoral components should be made from cobalt chrome. *Clin Orthop* 1995 Apr;(313):146-53.
5. **Macalino GE**, Springer JW, Rahman ZS, Vlahov D, Jones TS. Community-based programs for safe disposal of used needles and syringes. *J Acquir Immune Defic Syndr* 1998;18 (Suppl 1):S111-S119.
6. Strathdee SA, Celentano DD, Shah N, Lyles C, Stambolis MA, **Macalino GE**, Nelson K, Vlahov D. Needle exchange attendance and health care utilization to promote entry into detoxification. *J Urban Health* 1999; 76:448-460.
7. Rich JD, Dickinson BP, **Macalino GE**, Flanigan TP, Towe CW, Spaulding A, Vlahov D. Prevalence and incidence of HIV among incarcerated and reincarcerated women in Rhode Island. *J Acquir Immund Defic Syndr* 1999 Oct 1;22 (2):161-166.
8. Willy RJ, Salas CM, **Macalino GE**, Rich JD. Long-term non-progression of HIV-1 in a patient coinfectd with HTLV-II. *Diagn Microbiol Infect Dis* 1999 Dec;35(4):269-70.
9. Vlahov D, Tang A, Lyles C, Rezza G, Thomas D, Cohn S, **Macalino GE**, Stambolis V, Nelson KE. Increased frequency of overdose deaths among HIV infected injection drug users. *Addict Res* 2000; 8(4):311-326.
10. Rich JD, Strong LL, Mehrotra M, **Macalino GE**. Strategies to optimize the impact of needle exchange programs. *AIDS Read* 2000 Jul;10(7):421-9.
11. Rich JD, **Macalino GE**, McKenzie M, Taylor LE, Burris S. Syringe prescription to prevent HIV infection in Rhode Island; a case study. *Am J Public Health* 2001 May;91(5):699-700.
12. Rich JD, McKenzie, M, **Macalino GE**, Runnarsdottir V, Gaydos M, Mehrotra M, Stein J, Whitlock T, Salas C, Burris S. The genesis of syringe prescription to prevent HIV in Rhode Island. *Health Matrix Clevel* 2001 Winter; 11(1):129-45.
13. Rich JD, Holmes L, Salas C, **Macalino GE**, Davis D, Ryczek J, Flanigan T. Successful linkage of medical care and community services for HIV positive offenders being released from prison. *J Urban Health*, 2001; 78(2):279-289.
14. Charuvastra A, Stein J, Schwartzapfel B, Spaulding A, Horowitz E, **Macalino G**, Rich JD. Hepatitis B vaccination practices in state and federal prisons. *Public Health Rep* 2001 May-Jun;116(3):203-9.
15. Mitty JA, Stone VE, Sands M, **Macalino GE**, Flanigan T. Directly observed therapy for the treatment of

people with human immunodeficiency virus infection: a work in progress. *Clin Infect Dis* 2002 Apr 1;34(7):984-90.

16. Spaulding A, Stephenson B, **Macalino GE**, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. *Clin Infect Dis* 2002 Aug 1;35(3):305-12.
17. Rich JD, **Macalino G**, Merchant RC, Salas C, Marcussen P, Grundy M, Spaulding A. HIV seroprevalence of adult males incarcerated for a sexual offense in Rhode Island, 1994-1999. *JAMA* 2002 Jul 10; 288(2):164-5.
18. **Macalino GE**, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer assisted self-interviews among HIV seropositive and seronegative injection drug users. *AIDS Educ Prev* 2002 Oct;14(5):367-78.
19. Rich JD, Martin EG, **Macalino GE**, Paul RV, McNamara S, Taylor LE. Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island. *J Am Pharm Assoc (Wash)*. 2002 Nov-Dec;42 (6 Suppl 2):S58-61.
20. Rich JD, Wolf Francis, **Macalino GE**. Strategies to Improve Access to Sterile Syringes for Injection Drug Users. *AIDS Read V* 12 (12) 2002 Dec, 527-35.
21. Taylor LE, Runarsdottir V, Zampi A, Osei A, Sanford S, **Macalino GE**, McKenzie M, Burris S, Merik Gross JD, Reinert SE, Rich JD. Would you consider prescribing syringes to Injection Drug Users? Addiction Medicine Conference Survey *J Addict Dis* 2003 22(1) 67-78.
22. **Macalino GE**, Ko H, Celentano DD, Hogan JW, Schoenbaum EE, Schuman P, Rich JD. Drug use patterns over time among HIV seropositive and HIV seronegative women: The HER study experience. *J Acquir Immune Defic Syndr* 2003; 1;33(4):500-505.
23. **Macalino GE**, Weston RS, Wolf FA, Sanford-Colby SL, McKenzie MM, Rich JD. Acceptability and utility of a hand held syringe disposal device for active injection drug users. *J Drug Issues* 2003 33(2): 519-532.
24. Adelson-Mitty J, **Macalino G**, Taylor L, Harwell J, Flanigan T. Directly Observed Therapy (DOT) for Individuals With HIV: Successes and Challenges [article]. *Medscape, Medscape General Medicine* 2003; 5(1). <http://www.medscape.com/viewarticle/448428>
25. Harwell JI, Flanigan TP, Mitty JA, **Macalino GE**, Caliendo AM, Ingersoll J, Stenzel MS, Carpenter CC, Cu-Uvin S. Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. *AIDS* 2003 5;17(13):1990-3.
26. **Macalino GE**, Vlahov D, Sanford S, Patel S, Sabin K, Salas C, Rich JD. Prevalence and incidence of human immunodeficiency virus, Hepatitis B and C virus infections among males in Rhode Island prisons. *Am J Public Health* 94 (7) 1218-23, 2004.
27. **Macalino GE**, Hou JC, Kumar MS, Taylor LE, Sumantera IG, Rich JD. Hepatitis C infection and incarcerated populations. *Int J of Drug Policy* 15(2):103-14, 2004.
28. Rich JD, McKenzie M, **Macalino GE**, Taylor L, Sanford-Colby S, Wolf F, McNamara S, Mehrotra M, Stein MD. A syringe prescription program to prevent infectious disease and improve health of injection drug users. Vol 81 Issue 1 March 2004.

29. **Macalino GE**, Mitty JA, Bazerman LB, Singh K, McKenzie M, Flanigan TP. Modified directly observed therapy for the treatment of HIV-seropositive substance users: Lessons learned from a pilot study. *Clin Infect Dis* 38(5):S393-7, 2004.
30. Vallabhaneni S, **Macalino GE**, Reinert SE, Schwartzapfel B, Wolf FA, Rich JD. Prisoners' Attitudes toward Hepatitis B vaccination. *Prev Med* 38(6):828-33, 2004.
31. Mitty JA, **Macalino GE**, Bazerman LB, Loewenthal HG, Hogan JW, MacLeod CM, Flanigan TP. The Use of Community-Based Modified Directly Observed Therapy for the Treatment of HIV-Infected Persons. *Journal of Acquired Immune Deficiency Syndromes*.39(5):545-550, August 15, 2005.
32. **Macalino GE**, Vlahov D, Dickinson BP, Schwartzapfel B, Rich J. Community Incidence of Hepatitis B and C Among Re-Incarcerated Women. *Clin Infect Dis* 41(7):998-1002, Oct 2005.
33. **Macalino GE**, Dhawan D, Rich J. A Missed Opportunity: Hepatitis C Screening of Prisoners. *Am J Public Health* 95: 1739-1740, Oct 2005
34. Beletsky L, **Macalino G**, Burris S. Attitudes of Police Officers Towards Syringe Access, Occupational Needle-sticks, and Drug Use: A Qualitative Study of One City Police Department in the United States. *International Journal of Drug Policy* 16(4): 267-274, 2005.
35. McKenzie, M, **Macalino, G**, McClung, C, Shield, DC, Rich, JD. Opiate replacement therapy at time of release from incarceration: Project MOD, a pilot program. *Journal of Opioid Management*, 147-151 July/August 2005.
36. S. Vallabhaneni, **GE Macalino**, SE Reinert, B Schwartzapfel, FA Wolf, JD Rich. Prisoners favour hepatitis C testing and treatment. *Epidemiol. Infect.* 134(2):243-248, 2006
37. Beletsky L, Ruthazer R, **Macalino GE**, Rich JD, Tan L, Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. *J Urban Health*. 84 (1), 126-137, Jan 2007.
38. Beckwith CG, Atunah-Jay S, Cohen J, **Macalino G**, Poshkus M, Rich JD, Flanigan TP, Lally MA. Feasibility and acceptability of rapid HIV testing in jail. *AIDS Patient Care STDS*. 2007 Jan;21(1):417.
39. **Macalino GE**, Hogan J, Mitty JA, Bazerman L, DeLong A, Loewenthal H, Caliendo AM, Flanigan TP. A Randomized Clinical Trial of Community Based Directly Observed Therapy (MDOT) as an Adherence Intervention for Highly Active Antiretroviral Therapy (HAART) among Substance Users. *AIDS*, 2007 Jul 11;21 (11):1473-7.
40. Boyer EW, Babu KM, **Macalino GE**, Self-treatment of opioid withdrawal with a dietary supplement, Kratom. *Am J Addict*. 2007 Sep-Oct;16 (5):352-6.
41. Boyer EW, Lapen PT, **Macalino G**, Hibberd PL. Dissemination of psychoactive substance information by innovative drug users. *Cyberpsychol Behav*. 2007 Feb;10 (1):1-6.
42. **Macalino GE**, Sachdev DD, Rich JD, Becker C, Tan LJ, Beletsky L, Burris S. A national physician survey on prescribing syringes as an HIV prevention measure. *Subst Abuse Treat Prev Policy*. 2009 Jun 8;4:13. PubMed PMID: 19505336; PubMed Central PMCID: PMC2700789.

43. Fraser M, Brown H, Homel P, Macchia RJ, LaRosa J, Clare R, Davis-King D, Collins P, Samuel T, **Macalino G**, Browne RC. Barbers as lay health advocates--developing a prostate cancer curriculum. *J Natl Med Assoc.* 2009 Jul;101(7):690-7. PubMed PMID: 19634590.
44. Crum-Cianflone NF, Roediger M, Eberly LE, Vyas K, Landrum ML, Ganesan A, Weintrob AC, Barthel RV, Agan BK; **Infectious Disease Clinical Research Program HIV Working Group.** Obesity among HIV-infected persons: impact of weight on CD4 cell count. *AIDS.* 2010 Apr 24;24(7):1069-72. PubMed PMID: 20216300; PubMed Central PMCID: PMC2878190.
45. Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN; **Infectious Disease Clinical Research Program HIV Working Group.** A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV- infected adults. *J Infect Dis.* 2010 Oct 1;202(7):1114-25. PubMed PMID: 20795819; PubMed Central PMCID: PMC2932785.
46. Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, Ganesan A, Landrum M, Weintrob A, Agan B, Medina S, Rahkola J, Hale B, Janoff EN; **Infectious Disease Clinical Research Program HIV Working Group.** The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. *Vaccine.* 2010 Nov 10;28(48):7583-8. Epub 2010 Sep 29. PubMed PMID: 20887830; PubMed Central PMCID: PMC2981674.
47. Crum-Cianflone NF, Eberly LE, Duplessis C, Maguire J, Ganesan A, Faix D, Defang G, Bai Y, Iverson E, Lalani T, Whitman T, Blair PJ, Brandt C, **Macalino G**, Burgess T. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immune- compromised population: a prospective study comparing HIV-infected adults with HIV- uninfected adults. *Clin Infect Dis.* 2011 Jan;52(1):138-46. Epub 2010 Dec 7. PubMed PMID: 21148532.
48. Stermole BM, Grandits GA, Roediger MP, Clark BM, Ganesan A, Weintrob AC, Crum- Cianflone NF, Ferguson TM, **Macalino GE**, Landrum ML. Long-term safety and serologic response to measles, mumps, and rubella vaccination in HIV-1 infected adults. *Vaccine.* 2011 Apr 5; 29(16): 2874-80.
49. Crum-Cianflone NF, Iverson E, Defang G, Blair PJ, Eberly LE, Maguire J, Ganesan A, Faix D, Duplessis C, Lalani T, Whitman T, Brandt C, **Macalino G**, Millar EV, Burgess T. Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza ! (H1N1) vaccine among HIV- infected and HIV-uninfected adults. *Vaccine.* 2011 Apr 12; 29(17):3183-91.
50. Pollini RA, Rosen PC, Gallardo M, Robles B, Brouwer KC, **Macalino GE**, Lozada R. Not sold here: Limited access to legally available syringes at pharmacies in Tijuana, Mexico. *Harm Reduction J.* 2011 May 24;9(1):13.
51. Lifson AR, Krantz EM, Grambsch PL, **Macalino GE**, Crum-Cianflone NF, Ganesan A, Okulicz JF, Eaton A, Powers JH, Eberly LE, Agan BK; **Infectious Disease Clinical Research Program HIV/STI Working Group.** Clinical, demographic and laboratory parameters at HAART initiation associated with decreased post-HAART survival in a U.S. military prospective HIV cohort. *AIDS Res Ther.* 2012 Feb 10;9(1):4. doi: 10.1186/1742-6405-9-4. PubMed PMID: 22339893; PubMed Central PMCID: PMC3320559.

52. Ganesan A, Fieberg A, Agan BK, Lalani T, Landrum ML, Wortmann G, Crum-Cianflone NF, Lifson AR, **Macalino G**; Infectious Disease Clinical Research Program HIV Working Group. Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care. *Sex Transm Dis.* 2012 Jun;39(6):440-8. PubMed PMID: 22592829
53. Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, Ross MJ, Crum-Cianflone NF; Infectious Disease Clinical Research Program HIV/STI Working Group. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. *HIV Med.* 2013 Feb;14(2):65-76. PubMed PMID: 22808988.
54. Agan BK, **Macalino GE**, Nsouli-Maktabi H, Wang X, Gaydos JC, Ganesan A, Kortepeter MG, Sanchez JL. Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service. *MSMR.* 2013 Feb;20(2):21-4. PubMed PMID: 23461307.
55. Tsai AY, Dueger E, **Macalino GE**, Montano SM, Tilley DH, Mbuchi M, Wurapa EK, Saylor K, Duplessis CC, Pupilampu N, Garges EC, McClelland RS, Sanchez JL. The U.S. military's *Neisseria gonorrhoeae* resistance surveillance initiatives in selected populations of five countries. *MSMR.* 2013 Feb;20(2):25-7. PubMed PMID: 23461308.
56. Blazes DL, Bondarenko JL, Burke RL, Vest KG, Fukuda MM, Perdue CL, Tsai AY, Thomas AC, Chandrasekera RM, Cockrill JA, Von Thun AM, Baliga P, Meyers M, Quintana M, Wurapa EK, Mansour MM, Dueger E, Yasuda CY, Lanata CF, Gray GC, Saylor KE, Ndip LM, Lewis S, Blair PJ, Sloberg PA, Thomas SJ, Lesho EP, Grogl M, Myers T, Ellison D, Ellis KK, Brown ML, Schoepp RJ, Shanks GD, **Macalino GE**, Eick-Cost AA, Russell KL, Sanchez JL. Contributions of the Global Emerging Infections Surveillance and Response System Network to global health security in 2011. *US Army Med Dep J.* 2013 Apr-Jun;7:18. PubMed PMID: 23584903.
57. McNamara BC, Losikoff PT, Huguenin L, **Macalino GE**, Rich JD, Gregory SH. Increasing hepatitis C prevalence and associated risk behaviors among incarcerated young adults. *J Urban Health.* 2014 Apr;91(2):376-82. PubMed PMID: 23722268.
58. Bebu I, Tate J, Rimland D, Mesner O, **Macalino GE**, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy. *J Acquir Immune Defic Syndr.* 2014 Feb 1;65(2):226-30. PubMed PMID: 24226058.
59. Sánchez JL, Agan BK, Tsai AY, **Macalino GE**, Wurapa E, Mbuchi M, Dueger E, Horton KC, Montano-Torres SM, Tilley DH, Saylor KE, Pupilampu N, Duplessis CC, Harrison DJ, Putnam SD, Garges EC, Espinosa BJ, Dejl J, Meyers M, Yingst SL, Jerse AE, Maktabi HH, Burke RL, Jordan NN, Nowak G, Hsu K, Soge OO, Holmes KK, McClelland RS, MacDonald MR, Pavlin JA, Gaydos JC, Tramont EC. Expanded sexually transmitted infection surveillance efforts in the United States military: a time for action. *Mil Med.* 2013 Dec;178(12):1271-80. Review. PubMed PMID: 24306007.
60. Johnson EN, Roediger MP, Landrum ML, Crum-Cianflone NF, Weintrob AC, Ganesan A, Okulicz JF, **Macalino GE**, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Race/ethnicity and HAART initiation in a military HIV infected cohort. *AIDS Res Ther.* 2014 Jan 24;11(1):10. doi: 10.1186/1742-6405-11-10. PubMed PMID: 24460764.
61. Chun HM, Mesner O, Thio CL, Bebu I, **Macalino G**, Agan BK, Bradley WP, Malia J, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Bavaro M, Maguire JD, Landrum ML; Infectious Disease Clinical Research Program HIV Working Group. HIV outcomes in Hepatitis B virus coinfecting individuals on HAART. *J Acquir Immune Defic Syndr.* 2014 Jun 1;66(2):197-205. PubMed PMID: 24694929.

62. Sachdev DD, Stojanovski K, Liu AY, Buchbinder SP, **Macalino GE**. Intentions to prescribe preexposure prophylaxis are associated with self-efficacy and normative beliefs. *Clin Infect Dis*. 2014 Jun;58(12):1786-7. PubMed PMID: 24729556.
63. Ganesan A, Mesner O, Okulicz JF, O'Bryan T, Deiss RG, Lalani T, Whitman TJ, Weintrob AC, **Macalino G**, Agan BK; Infectious Disease Clinical Research Program HIV/STI Working Group. A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis. *Clin Infect Dis*. 2015 Feb 15;60(4):653-60. PubMed PMID: 25389249.
64. Masel J, Deiss RG, Wang X, Sanchez JL, Ganesan A, **Macalino GE**, Gaydos JC, Kortepeter MG, Agan BK. Seroprevalence and seroincidence of herpes simplex virus (2006-2010), syphilis (2006-2010), and vaccine-preventable human papillomavirus subtypes (2000-2010) among US military personnel. *Sex Transm Dis*. 2015 May;42(5):253-8. PubMed PMID: 25868137.
65. Deiss RG, Mesner O, Agan BK, Ganesan A, Okulicz JF, Bavaro M, Lalani T, O'Bryan TA, Bebu I, **Macalino GE**. Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy. *Alcohol Clin Exp Res*. 2016 Mar;40(3):529-35. Pubmed PMID: 26916712.
66. Koren M, Wang X, Blaylock JM, Okulicz JF, Whitman TJ, Deiss RG, Ferguson TM, O'Bryan TA, Sanchez JL, Lalani T, Agan BK, **Macalino GE**, Ganesan A. [The epidemiology of herpes simplex virus type 2 infections in a large cohort of HIV-infected patients, 2006-2014](#). *MSMR*. 2016 Mar; 23(3):11-5. PMID: 27030927.
67. Emuren L, Welles S, Evans AA, Polansky M, Okulicz JF, **Macalino G**, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. [Health-related quality of life among military HIV patients on antiretroviral therapy](#). *PLoS One*. 2017 Jun 7;12(6):e0178953.
68. Mangal TD; UNAIDS Working Group on CD4 Progression and Mortality Amongst HIV Seroconverters including the CASCADE Collaboration in EuroCoord. [Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection](#). *AIDS*. 2017 May 15;31(8):1073-1082.
69. Deiss R, Bower RJ, Co E, Mesner O, Sanchez JL, Masel J, Ganesan A, Macalino GE, Agan BK. [The Association between Sexually Transmitted Infections, Length of Service and Other Demographic Factors in the U.S. Military](#). *PLoS One*. 2016 Dec 9;11(12):e0167892. doi: 10.1371/journal.pone.0167892. eCollection 2016.

CHAPTERS IN BOOKS

1. Engh CA, McGovern TF, Engh, Jr. CA, **Macalino GE**. Clinical experience with the Anatomic Medullary Locking (AML) prosthesis for primary total hip replacement in: *Biological, material, and mechanical considerations of joint replacement: Current concepts and future direction*, Morrey BF (Ed.). Raven Press, New York, 1993.
2. Engh CA and **Macalino GE**. Clinical results of revision surgery: are we doing better using extensively porous-coated stems? in: Galante JO, Rosenberg AG, Callaghan JJ, eds. *Total hip revision surgery*, Raven Press, New York, 1995.
3. **Macalino GE** and Engh CA. Cementless acetabular components: porous vs. threaded in *Noncemented Hip and Knee Prosthesis*, Hans Huber Publisher, 1995.

4. **Macalino GE.** Hepatitis C virus infection among incarcerated women in: *Health Issues Among Incarcerated Women*, Rutgers University Press, New Jersey, 2006.

ACCEPTED POSTER ABSTRACTS

1. Sotereanos NG, Engh CA, **Macalino GE.** 1995 American Association of Orthopaedic Surgeons (AAOS) Annual Meeting: Long-term results of suboptimally fixed AML prostheses. Orlando Florida (February 16-20, 1995).
2. Hilton CM, **Macalino GE,** Ireys H, Taylor H, Chernoff R, Pilowsky D, Vlahov D. 1996, 11th International Conference on AIDS: Legacy House: A Project for Affected Children of HIV. Vancouver Canada (July 7-12, 1996).
3. **Macalino GE,** Celentano D, Hilton C, McFadden C, Vlahov D. 1996, 11th International Conference on AIDS: Vaginal Microbicide Use: Knowledge and Attitudes in a cohort of intravenous drug users. Vancouver Canada (July 7-12, 1996).
4. **Macalino GE,** Lyles C, Shah N, Quinn T, Astemborski J, Vlahov D. Initial viral load soon after seroconversion has not increased between 1988 and 1997 in a cohort of US inner-city injection drug users. 12th World AIDS Conference, Geneva Switzerland (June 28-July 3, 1998).
5. Sterling T, Lyles C, Quinn TC, Quinn T, Astemborski J, Margolick J, **Macalino GE,** Vlahov D. Gender-specific differences in HIV-1 RNA levels in a longitudinal study of HIV-1 seroconverters. 12th World AIDS Conference, Geneva Switzerland (June 28-July 3, 1998).
6. Kopp JB, Vlahov D, **Macalino GE,** Briggs WA, Korbet SM, et al. Candidate gene analysis in focal segmental Glomerulosclerosis among African-Americans. American Society of Nephrology, 31st Annual Scientific Meeting, Philadelphia PA (October 25-28, 1998).
7. Rich JD, **Macalino GE,** Dickinson B, Flanigan T. American Public Health Association Annual Meeting: Community incidence and prevalence in a population of incarcerated women. Washington DC (November 15-19, 1998).
8. **Macalino GE,** Celentano DD, Kuo I, Strathdee S, Vlahov D. A comparison of audio computer-assisted self interviews (ACASI) to interviewer-administered questionnaires (IAQ) among a cohort of injection drug users (IDUs). Poster presentation, Society of Epidemiological Research Annual Meeting, Baltimore MD (June 1999).
9. **Macalino GE,** Safeian M, Strathdee S, Vlahov D. Temporal trends and risk factors associated with HIV seroconversion in the ALIVE Study (1988-1997). Oral presentation, Conference on Problems in Drug Dependence, Acapulco Mexico (June 14, 1999).
10. Rich JD, **Macalino GE,** Dickinson B, Flanigan T. CDC HIV Prevention Conference: Community incidence and intake prevalence in a population of incarcerated women. Atlanta GA (August 29-September 1, 1999).
11. Rich JD, McKenzie M, Gaydos M, **Macalino G.** Syringe prescription to prevent the spread of HIV. (Abstract 611) 1999 National HIV Prevention Conference, Atlanta GA (September 1999).

12. **Macalino GE**, Salas CM, Towe CW, Foisie CK, McKenzie M, Spaulding A, Rich JD. Incidence and community prevalence of HIV and other blood borne pathogens among incarcerated women in Rhode Island. (Abstract 610) 1999 National HIV Prevention Conference, Atlanta GA (September 1999).
13. Gaydos M, McKenzie M, **Macalino GE**, Salsas C, Rich JD. Methodological approaches to assessing incidence of blood borne pathogens in the RI Department of Corrections: The Rhode Island Prison Study. Immunology Center, The Miriam Hospital, Providence RI (November 1999).
14. **Macalino GE**, Celentano DD, Kuo I, Mehta SH, Strathdee S, Vlahov D. Assessing the validity of self-reported HIV risk behaviors collected by audio computer-assisted self interview (ACASI) among a cohort of injection drug users (IDUs). Roundtable Presentation, American Public Health Association Annual Meeting, Chicago IL (November 1999).
15. **Macalino GE**, Rich JD, Salas C, Gaydos ME, McKenzie M. Physician prescribing of syringes to prevent HIV. 10th North American Syringe Exchange Convention, Portland OR (April 2000).
16. Rich JD, Mehrotra M, Whitlock TL, Gaydos ME, McKenzie M, Runarsdottir V, Gormley J, Aboagye-Kumi M, **Macalino G**, Salas C. Physician prescribing of syringes to prevent HIV. Journal of General Internal Medicine, V. 15, Suppl 1, April 2000 Society of General Internal Medicine 23rd Annual Meeting, Boston MA (May 2000).
17. **Macalino GE**, Lyles C, Latkin C, Vlahov D, Strathdee SA, Celentano DD. Extent of mis-reporting of self-reported HIV risk behaviors on interviewer administered questionnaires (IAQs) compared to audio computer-assisted self interviews (ACASI) among injection drug users. Oral presentation, 13th International Conference on AIDS, Durban South Africa (July 9-14, 2000).
18. **Macalino GE**, Salas CM, Rich J, Vlahov D. Prevalence and incidence of HIV and other bloodborne pathogens among inmates in Rhode Island. Oral presentation, National Correctional Health Care Conference, St Louis MO (September 2000).
19. Rich JD, McKenzie M, **Macalino G**, Mehrotra M, Gaydos ME, Stein J, Whitlock TL, Runarsdottir V. Physician syringe prescription as a conduit to substance abuse treatment: A pilot intervention. Poster Presentation, Addictions 2000, Hyannis MA (September 22-24, 2000).
20. **Macalino GE**, Salas CM, Rich J, Vlahov D. HIV and other bloodborne pathogens among incarcerated populations: an opportunity for prevention. Oral presentation, National Harm Reduction Conference, Miami FL (October 2000).
21. **Macalino GE**. The U.S. response to drug use and its impact on HIV/AIDS. 9th Annual National Epidemiology Society of Indonesia, Jakarta Indonesia, (November 2000).
22. Spaulding A, Salas C, Cleaver D, Grundy M, **Macalino G**, Marcussen P, Rich J. HIV seroprevalence in male sexual offenders in Rhode Island: Implications for post exposure prophylaxis. Poster Presentation, 8th Conference on Retroviruses and Opportunistic Infections, Chicago IL (February 4-8, 2001).
23. **Macalino GE**, Salas CM, Rich J, Hannigan K, Spaulding A, Vlahov D. Intake prevalence and intraprisn transmission of HIV and other bloodborne pathogens among incarcerated men and women in Rhode Island. Poster Presentation, 34th Annual SER Meeting, Toronto Canada. (June 2001).

24. Flanigan TP, McKenzie M, **Macalino G**, Cu-Uvin S, Mitty J, Urbina B. The feasibility of directly observed therapy (DOT) among HIV+ substance users: A pilot study. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, Buenos Aires Argentina. (July 8-11, 2001).
25. McKenzie M, Rich JD, Paul RV, Olson JL, Osei A, McKenzie M, **Macalino G**. Physician prescribing syringes to prevent HIV and Hepatitis: A pilot intervention. (Abstract 585) 2001 HIV Prevention Conference, Atlanta GA (August 12-15, 2001).
26. Rich JD, Morrow K, Cunliffe T, Taylor L, Zampi A, Osei A, McKenzie M, **Macalino G**. Motivational enhancement for physicians prescribing syringes to injection drug users to prevent HIV. (Abstract 654) 2001 National HIV Prevention Conference, Atlanta GA (August 12-15, 2001).
27. Rich JD, Holmes L, Salas C, **Macalino G**, Davis D, Ryczek J, Flanigan T. Linkage of medical care and community services for HIV+ offenders being released from prison as secondary prevention. (Abstract 662) 2001 National HIV Prevention Conference, Atlanta GA (August 12-15, 2001).
28. Cu-Uvin S, Mitty J, Carpenter CCJ, Caliendo A, Stenzel M, Donahue S, Allega J, McKenzie M, **Macalino G**, Chapman T, Flanigan T. Effect of daily directly observed therapy (DOT) on genital tract and plasma HIV-1 RNA in HIV-infected substance abusing women: A pilot study. 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco CA (October 25-28, 2001).
29. Harwell JI, Martin EG, Sanford SL, **Macalino GE**, Taylor LE, Osei A, McNamara SF, Rich JD. Sexual risk behaviors and epidemic HIV and Hepatitis B among injection drug users receiving prescription for syringes. 2002 National STD Prevention Conference, San Diego CA (March 2002).
30. Rich JD, **Macalino GE**, Sanford-Colby S, McNamara S, Osei A, Stozek M. The effect of a syringe prescription intervention in decreasing HIV among injection drug users (IDUs) in Rhode Island. (Conference CD-ROM: D11319) XIV International AIDS Conference, Barcelona Spain (July 7-12, 2002).
31. **Macalino GE**, Vlahov D, Sanford-Colby S, Salas CM, Rich J. Intake prevalence and intraprison incidence of HIV, Hepatitis B (HBV), and Hepatitis C (HCV) among sentenced inmates in Rhode Island, USA. Poster presentation, XIV International AIDS Conference, Barcelona Spain (July 10, 2002).
32. Chapman S, Macleod C, Sliney A, Dicesare R, McNamara S, **Macalino GE**, Mitty J. The Impact of Nursing on High Risk HIV+ Individuals, Engaged in Directly Observed Therapy (DOT), to Increase Adherence with Medical Appointments. Oral presentation, 15th Annual Conference, Association of Nurses in AIDS Care, San Francisco, CA, (November 7-10, 2002).
33. Sanford-Colby S, **Macalino GE**, Mitty J, Flanigan TP. Evaluating a Clinical Trial to Administer Directly Observed Therapy (DOT) with HIV Antiretrovirals. Elements of Success: an International Conference on Adherence to Antiretroviral Therapy, Dallas TX (December 5-8, 2002).
34. **Macalino. GE**, Sanford-Colby S, Mitty J, Flanigan TP. Cost-effectiveness evaluation of a Directly Observed Therapy (DOT) program for HIV Antiretroviral Medications: Practical Considerations. Elements of Success: an International Conference on Adherence to Antiretroviral Therapy, Dallas TX (December 5-8, 2002).
35. McNamara S, Sanford-Colby S, **Macalino GE**. An evaluation of the Eureka! Sharpsmart program in Rhode Island. Oral presentation, NEARC 2003 Conference, Newport RI (November 2-5, 2003).

36. Sanford-Colby SL, Zierler S, McNamara SF, **Macalino GE**. Geographic information systems (GIS) technology to measure pharmacy proximity in relation to neighborhood racial/ethnic composition. Poster Presentation, APHA 131st Annual Meeting, San Francisco CA (November 15-19, 2003).
37. McNamara SF, **Macalino GE**, Sanford-Colby SL, Becker C, Thurmond P, Zierler S. The evaluation of racial/ethnic disparities in the implementation of a syringe deregulation law in Rhode Island: Practical considerations of a purchaser trial. Poster presentation, APHA 131st Annual Meeting, San Francisco CA (November 18, 2003).
38. Sanford-Colby SL, McKenzie SM, **Macalino GE**, McNamara SF, Rich JD. Injection drug users' use of physician prescriptions for free sterile syringes. Poster presentation, APHA 131st Annual Meeting, San Francisco CA (November 15-19, 2003).
39. **Macalino GE**, Mitty JA, Bazerman LB, McKenzie M, Flanigan TP. Directly observed therapy (DOT) for the treatment of HIV seropositive substance users: Lessons learned from a pilot study. Poster presentation, APHA 131st Annual Meeting, San Francisco CA (November 15-19, 2003).
40. **Macalino GE**, McNamara S, Sanford-Colby S, Case T, Zierler S. The evaluation of racial/ethnic disparities in the implementation of a syringe deregulation law in Rhode Island, USA. XVth International AIDS Conference, Bangkok, Thailand (July 13, 2004). (Abstract # TuOrC1111).
41. **Macalino GE**. Infectious disease research in the incarcerated setting: Lessons learned. National Conference on Correctional Health Care, New Orleans, LA (November 13-17, 2004).
42. Mkaya Mwamburi, **Grace Macalino**, John Griffith, Jennifer Mitty, Ira Wilson, Peter Neumann, Christine Wanke, Timothy Flanigan, John Wong, A cost effectiveness analysis evaluating immediate MDOT for HAART versus 3-month observation delay. Accepted for Poster Presentation, XVIth International AIDS conference, Toronto, CA (August 2006).
43. Mkaya Mwamburi, **Grace Macalino**, John Griffith, Jennifer Mitty, Ira Wilson, Peter Neumann, Christine Wanke, Timothy Flanigan, John Wong, Cost-Effectiveness Analysis of Modified Directly Observed Therapy (MDOT) for HAART for Patients with Poor Adherence. Accepted for Poster Presentation, XVIth International AIDS conference, Toronto, CA (August 2006).
44. McKenzie M, Thurmond P, **Macalino GE**, Rich J. Linking opiate addicted ex-offenders to community methadone treatment: Comparing 12 month outcomes based on retention in treatment. Accepted for Poster Presentation, #139124, 134th Annual American Public Health Association Meeting & Exposition, Boston, MA (November 4-8, 2006).
45. Thurmond P, McKenzie M, **Macalino GE**, Rich J. Managing opiate dependency (MOD): Evaluation of the effectiveness of a methadone maintenance linkage program. Accepted for Poster presentation #140416, 134th Annual American Public Health Association Meeting & Exposition, Boston, MA (November 4-8, 2006).
46. Tonya Samuel, MSPH, Karen Carapetyan, MA, Marilyn A. Fraser-White, MD, Ruth C. Browne, ScD, Julia A. Smith, MDPhD, **Grace Macalino, PhD**. Nuestra Belleza: The Health and Beauty of the Latina Woman—Ovarian Cancer Beauty Salon Project. American Public Health Association 136th Annual Meeting, San Diego, CA (November 2008).

47. Sexually Transmitted Infections and Predictive Sexual Risk Behaviors Among HIV+ Military Cohort Participants. **Macalino G**, Mesner O, Ganesan A, Deiss R, Okulicz J, Lalani T, Agan B. IDWeek, San Diego, CA, October 2015.
48. The Epidemiology and risk factors associated with Herpes Simplex Virus [HSV]-2 infections in a large well-characterized cohort of HIV infected patients – 2006-2014. Koren M, Wang X, Okulicz J, Blaylock J, Whitman T, Deiss R, O'Bryan T, Lalani T, Agan B, **Macalino G**, Ganesan A. IDWeek, San Diego, CA, October 2015.
49. Repeat syphilis infections in a cohort of HIV-infected Department of Defense Beneficiaries (DoD), a thirty year study (1986-2015). Ganesan A, Mesner O, Deiss R, Okulicz J, Lalani T, Whitman T, O'Bryan T, Ferguson T, **Macalino G**, Agan B. IDWeek, San Diego, CA, October 2015.
50. Incidence of sexually transmitted infections (STIs) in the U.S. military is associated with female gender, increased length of service and non-deployment. Deiss R, Mesner O, Bower R, Sanchez J, Co E, Ganesan A, **Macalino G**, Agan B. IDWeek, San Diego, CA, October 2015.
51. STI diagnosis prior to HIV infection may severely underestimate HIV risk among active duty military members. Glancey M, Agan B, Chu X, Mesner O, Sanchez J, Ganesan A, Deiss R, **Macalino G**. IDWeek, San Diego, CA, October 2015.
52. Hepatitis B virus infection and association with sexually transmitted infections among U.S. military personnel. Troja C, Deiss R, Mesner O, Sanchez J, Co E, Ganesan A, **Macalino G**, Agan B. IDWeek, San Diego, CA, October 2015.
53. Incidence of sexually transmitted infections (STIs) in the U.S. military is associated with female gender, increased length of service and non-deployment. Deiss R, Mesner O, Bower R, Sanchez J, Co E, Ganesan A, **Macalino G**, Agan B. IDWeek, San Diego, CA, October 2015.
54. Sexually Transmitted Infections and Predictive Sexual Risk Behaviors Among HIV+ Military Cohort Participants. **Macalino G**, Mesner O, Ganesan A, Deiss R, Okulicz J, Lalani T, Agan B. Conference on Retroviruses and Opportunistic Infections (CROI), February 22-25, 2016, Boston MA.
55. Sexually Transmitted Infections and Predictive Sexual Risk Behaviors Among HIV+ Military Cohort Participants. Macalino G, Byrne M, Ganesan A, Okulicz J, Lalani T, Bavaro M, Agan B. Poster presentation. Military Health System Research Symposium, August 15-18, 2016, Kissimmee, FL.
56. STI Diagnosis Prior to HIV May Severely Underestimate HIV Risk Among US Military Personnel. Oral presentation: Glancey M, Ganesan A, Deiss R, Okulicz J, Lalani T, Schofield C, Agan B, **Macalino G**. Military Health System Research Symposium, August 15-18, 2016, Kissimmee, FL.
57. Identifying STI Risk Profiles among HIV+ Military Cohort Members using Multidimensional Scaling Profile Analysis. Poster presentation. **Macalino G**, Byrne M, Deiss R, Ganesan A, Lalani T, Schofield C, Okulicz J, Agan B. STD Prevention Conference, September 20-23, 2016, Atlanta, GA.
58. Sexual Risk Behaviors and STI trends among HIV+ Military Male Cohort Members who Utilize Internet Social Networking Sites for Partner Solicitation. Poster presentation. Byrne M, Schofield C, Okulicz J, Deiss R, Ganesan A, Lalani T, Agan B, **Macalino G**. STD Prevention Conference, September 20-23, 2016, Atlanta, GA.
59. STIs Prior to HIV in an HIV+ US Military Population. Poster presentation. Glancey M, Ganesan A, Deiss R, Okulicz J, Lalani T, Schofield C, Agan B, Macalino G. STD Prevention Conference, September 20-23, 2016, Atlanta, GA.

60. Gonococcal Resistance in a population of at-risk U.S. DoD Beneficiaries. **Macalino G**, Kluz N, Rahman N, Byrne M, Sanchez J, Berry-Caban C, Roberts T, Deiss R, Lalani T, Jerse A. IDWeek, October 25-30, 2016, New Orleans, LA.
61. How Does Changing Sexual Risk Behaviors Impact Incident Sexually Transmitted Infections (STIs) in a Cohort of Human Immunodeficiency Virus (HIV) + Military Beneficiaries? **Macalino, PhD**, Wang, MS, Anuradha Ganesan, MD, MPH, Robert Deiss, MD, Tahaniyat Lalani, MD, Christina Schofield, MD FACP, FIDSA, Jason Okulicz, MD, Brian Agan, MD. IDWeek, October 25-30, 2016, New Orleans, LA.
62. Characterizing Self-reported Sexual Risk Behaviors and STIs among High Risk Military Population who Utilize Social Networking Sites to Seek Sexual Partners. Morgan Byrne, MPH; Nicole Kluz, MPH; Jose Sanchez, MD, MPH; Cristobal Berry-Caban, PhD; Rodd Marcum, MD; Tahaniyat Lalani, MD; Robert Deiss, MD; Timothy Roberts, MD; **Grace E Macalino, PhD**. IDWeek, October 25-30, 2016, New Orleans, LA.

PRESENTATIONS

REGIONAL PRESENTATIONS

- 2008 Brooklyn Health Disparities Center Community Forum “Health Disparities in Brooklyn”, Borough Hall, Brooklyn, NY
- 1999 Panel Discussant, “Clinical Trials in Corrections,” Providence, RI, 13-15 October

NATIONAL PRESENTATIONS

- 2019 Invited Speaker, Americans for Safe Access (ASA) Unity Conference, “Cascade of Care Model for Patients and Medical Cannabis Access. Washington DC, March
- 2014 Invited Speaker, CDC STD Prevention Conference, “Permanent Change of Station (PCS) and Syphilis Incidence Among Active Duty Members and Beneficiaries,” Atlanta, GA, 9-13 June
- 2007 NIDA Asian American Pacific Islander Meeting, Washington, DC
- 2005 Correctional Healthcare Meeting
- 2004 Invited Speaker, National Asian/Pacific Islander American Families Against Substance Abuse (NAPAFASA) Conference, “Bridging the Gap Between Research and Community Based Organizations.” Washington DC, June.
- 2003 Session Moderator, National AIDS Prevention Conference, Atlanta GA, August.
- 2003 Invited Speaker, 10th Conference on Retroviruses and Opportunistic Infections, “Key Components of Directly Observed Therapy Programs”. Boston, MA, February.
- 2003 Invited Speaker, HIV Adherence Symposium, Mt. Sinai Hospital. “Directly observed therapy as an adherence intervention among substance users.” New York, NY, January.
- 2001 Invited Speaker, CDC Consultants Meeting on Hepatitis in Corrections. “Prevalence and Incidence of Hepatitis among Rhode Island Inmates,” Atlanta GA 5-7 March

INTERNATIONAL PRESENTATIONS

- 2013 Invited Poster Presentation, 17th International Workshop on HIV Observational Databases (IWHOD), Cavtat, Croatia, April.
- 2002 Roundtable Presentation, International Harm Reduction Conference, Slovenia, March.
- 2000 Invited Speaker, 9th Annual National Epidemiology Society of Indonesia. “U.S. response to drug use and its impact on HIV/AIDS,” Jakarta Indonesia 11-13 November.